DukeSpace Home
→
Duke Scholarly Works
→
Browsing Duke Scholarly Works by Duke-affiliated Author

Browsing Duke Scholarly Works by Duke-affiliated Author "Grabowski, Henry G."

Now showing items 1-20 of 67

A Computer Simulation Model of Pharmaceutical Innovation

Grabowski, Henry G.; Vernon, John (Swedish Institute for Health Economics and Liber Forlag, 1984)
A Computer Simulation Model of Pharmaceutical Innovation

Grabowski, Henry G.; Vernon, John M. (Swedish Institute for Health Economics and Liber Forlag, 1984)
An Analysis of U.S. International Competitiveness in Pharmaceuticals

Grabowski, Henry G. (1989)
Are the Economics of Pharmaceutical R&D Changing? Productivity, Patents and Political Pressures

Grabowski, Henry G. (2004)

Pharmaceutical R&D competition in the 1980s and 1990s was characterized by rising R&D expenditures, favorable returns to innovators, and the introduction of many new classes of drugs with high social benefits. However in ...
A Sensitivity Analysis of Expected Profitability of Pharmaceutical Research and Development

John Vernon; Grabowski, Henry G. (1982-03)
Brand Loyalty, Entry and Price Competition in Pharmaceuticals After the 1984 Drug Act

Vernon, JM; Grabowski, Henry G. (1992-10)
Brand Loyalty, Entry, and Price Competition in Pharmaceuticals after the 1984 Drug Act

Grabowski, Henry; Vernon, John (Journal of Law and Economics, 1992-10)

IN 1984, Congress enacted a new law that greatly affected the economics of the pharmaceutical industry in the United States. It has been characterized as the most important legislation affecting competition in the ...
Competition between Generic and Branded Drugs

Grabowski, Henry G. (Cambridge University Press, 2007-04-30)

The pharmaceutical industry worldwide is a rapidly burgeoning industry contributing to growth of gross domestic product and employment. Technological change in this field has been very rapid, with many new products being ...
Consumer Protection Regulation in Ethical Drugs

Vernon, John M.; Grabowski, Henry G. (1977-02)
Demand Shifting, Optimal Firm Growth, and Rule-of-Thumb Decision Making

Grabowski, Henry G. (1970-05)
The Determinants of Industrial Research and Development: A Study of the Chemical, Drug, and Petroleum Industries

Grabowski, Henry (Journal of Political Economy, 1968)

Economists have recently grown interested in doing research on research or R & D, as it is called in industrial circles. Several studies have tested Schumpeter's hoary hypothesis that large firms are responsible for ...
Developing drugs for developing countries.

Ridley, DB; Grabowski, Henry G.; Moe, JL (2006-03)

Infectious and parasitic diseases create enormous health burdens, but because most of the people suffering from these diseases are poor, little is invested in developing treatments. We propose that developers of treatments ...
Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act

Grabowski, Henry; Wang, Richard (SSRN eLibrary, 2008)

times have significantly declined since the passage of PDUFA in 1992, while agency resources have expanded through user fees. After the recent withdrawal of Vioxx and other high-profile products, there have been increasing ...
Do Faster FDA Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act

Richard Wang, Y; Grabowski, Henry G. (2008-05)
Economic Evaluation of Drug Treatment for Psychiatric Disorders: The New Clinical Trial Protocol

Zarkin, Gary A.; Grabowski, Henry G.; Mauskopf, Josephine Mary; Bannerman, Heather A.; Weisler, Richard Harry (Raven Press, 1995)
Economic return of clinical trials performed under the pediatric exclusivity program.

Li, Jennifer. S; Eisenstein, Eric Leo; Grabowski, Henry G.; Reid, Elizabeth. D; Mangum, Barry; Schulman, Kevin Alan; Goldsmith, John V.; Murphy, M. Dianne; Califf, Robert M.; Benjamin, Daniel Kelly Jr. (2007-02-07)

In 1997, Congress authorized the US Food and Drug Administration (FDA) to grant 6-month extensions of marketing rights through the Pediatric Exclusivity Program if industry sponsors complete FDA-requested pediatric trials. ...
Encouraging innovative treatment of neglected diseases through priority review vouchers

Grabowski, Henry G.; Ridley, David B.; Moe, Jeffrey L. (Stanford University: The Walter H, Shorenstein Asia-Pacific Research Center, 2009-09-01)
Encouraging the Development of New Vaccines

Grabowski, Henry G. (2005)
Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry

Vernon, JM; Thomas, LG; Grabowski, Henry G. (1978-04)
Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry

Grabowski, Henry; Vernon, John; Thomas, Lacy Glenn (Journal of Law and Economics, 1978)

INNOVATION in the U.S. ethical drug industry in recent years has been characterized by a number of adverse developments. In particular, there has been a sharp decline in the rate of new product introductions and the ...